

Attorney Docket No. 5390 200-US
Dorwald et al.
Serial No 09/548,081, Filed April 12, 2000

Attorney Docket No.: 5390.200-US

**RECEIVED
CENTRAL FAX CENTER**

DEC 16 2004
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dorwald et al. Confirmation No.: 5691
Application No.: 09/548,081 Group Art Unit: 1624
Filed: April 12, 2000 Examiner: Liu, Hong
For: Substituted Imidazoles, Their Preparation and Use

**NOTICE OF APPEAL FROM THE EXAMINER
TO THE BOARD OF PATENT APPEALS AND INTERFERENCES**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant hereby appeals to the Board of Patent Appeals and Interferences from the last decision mailed June 25, 2004, of the Examiner finally rejecting claims numbered 102-105.

Please charge the required fee, estimated to be \$500, and any additional fees necessary for timely filing of this paper, and credit any overpayments to Novo Nordisk, Inc., Deposit Account No. 14-1447.

A copy of this sheet is enclosed.

Respectfully submitted,



Date: December 16, 2004

Rosemarie R. Wilk-Orescan
Registration Number 45, 220
Novo Nordisk, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5969

CUSTOMER NUMBER
23650

PATENT TRADEMARK OFFICE

Attorney Docket No. 5390.200-US
Dorwald et al.
Serial No. 09/548,081, Filed April 12, 2000

Attorney Docket No.: 5390.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dorwald et al. Confirmation No.: 5691
Application No.: 09/548,081 Group Art Unit: 1624
Filed: April 12, 2000 Examiner: Liu, Hong
For: Substituted Imidazoles, Their Preparation and Use

**NOTICE OF APPEAL FROM THE EXAMINER
TO THE BOARD OF PATENT APPEALS AND INTERFERENCES**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant hereby appeals to the Board of Patent Appeals and Interferences from the last decision mailed June 25, 2004, of the Examiner finally rejecting claims numbered 102-105.

Please charge the required fee, estimated to be \$500, and any additional fees necessary for timely filing of this paper, and credit any overpayments to Novo Nordisk, Inc., Deposit Account No. 14-1447.

A copy of this sheet is enclosed.

Respectfully submitted,



Date: December 16, 2004

Rosemarie R. Wilk-Orescan
Registration Number 45, 220
Novo Nordisk, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5969

CUSTOMER NUMBER
23650

PATENT TRADEMARK OFFICE